Exchange: NASDAQ·Updated 10:18 AM EDT
News
all
press releases
Halozyme to Participate at Upcoming Investor Conferences
Halozyme to Participate at Upcoming Investor Conferences Halozyme to Participate at Upcoming Investor Conferences PR Newswire SAN DIEGO, Sept. 2, 2026 SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced that Dr. Helen Torley, President...
PR Newswire
More News
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Zacks
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.
Zacks
Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?
Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Zacks
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
Zacks.com featured highlights Herbalife, Honda Motor, Marathon, Halozyme and Genworth
Herbalife, Honda Motor, Marathon, Halozyme and Genworth have been highlighted in this Screen of The Week article.
Zacks
5 Value Stocks to Buy Right Now as Inflation Remains Sticky
HLF, HMC, MPC, HALO and GNW screen as high-earnings-yield value picks as inflation stays elevated.
Zacks
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.
Zacks
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
Zacks
NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run?
NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks

Advertisement|Remove ads.